Cardiol Therapeutics (CRDL) Free Cash Flow: 2020-2024
Historic Free Cash Flow for Cardiol Therapeutics (CRDL) over the last 5 years, with Dec 2024 value amounting to -$18.3 million.
- Cardiol Therapeutics' Free Cash Flow rose 74.40% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$14.7 million, marking a year-over-year change of. This contributed to the annual value of -$18.3 million for FY2024, which is 2.09% up from last year.
- Cardiol Therapeutics' Free Cash Flow amounted to -$18.3 million in FY2024, which was up 2.09% from -$18.7 million recorded in FY2023.
- Cardiol Therapeutics' Free Cash Flow's 5-year high stood at -$6.8 million during FY2020, with a 5-year trough of -$21.0 million in FY2022.
- For the 3-year period, Cardiol Therapeutics' Free Cash Flow averaged around -$19.3 million, with its median value being -$18.7 million (2023).
- As far as peak fluctuations go, Cardiol Therapeutics' Free Cash Flow slumped by 174.56% in 2021, and later grew by 10.88% in 2023.
- Yearly analysis of 5 years shows Cardiol Therapeutics' Free Cash Flow stood at -$6.8 million in 2020, then slumped by 174.56% to -$18.8 million in 2021, then declined by 11.71% to -$21.0 million in 2022, then climbed by 10.88% to -$18.7 million in 2023, then increased by 2.09% to -$18.3 million in 2024.